Trial Profile
A Randomized, Blinded, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HQK-1001 in Subjects With Sickle Cell Disease
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 21 Mar 2014
Price :
$35
*
At a glance
- Drugs HQK 1001 (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions
- Sponsors HemaQuest Pharmaceuticals
- 21 Mar 2014 New trial record